Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 151 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Mikhailidis, Dimitri P  [Clear All Filters]
Journal Article
Tziomalos, K., Athyros V. G., & Mikhailidis D. P. (2009).  Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus.. Nat Clin Pract Endocrinol Metab. 5(1), 16-7.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Athyros, V. G., Ganotakis E. S., Tziomalos K., Papageorgiou A. A., Anagnostis P., Griva T., et al. (2010).  Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population.. Curr Med Res Opin. 26(3), 713-9.
Karagiannis, A., Athyros V. G., & Mikhailidis D. P. (2009).  A comparison of the aldosterone-blocking agents eplerenone and spironolactone.. Clin Cardiol. 32(4), 230.
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. Curr Vasc Pharmacol. 8(1), 1-4.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2015).  Contrast-Induced Nephropathy: An "All or None" Phenomenon?. Angiology. 66(6), 508-13.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  CORONA, statins, and heart failure: who lost the crown?. Angiology. 59(1), 5-8.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2011).  The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs. 20(3), 311-4.
Athyros, V. G., Tziomalos K., Mikhailidis D. P., Pagourelias E. D., Kakafika A. I., Skaperdas A., et al. (2007).  Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother. 8(14), 2267-77.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Kakafika, A. I., Liberopoulos E. N., Karagiannis A., Athyros V. G., & Mikhailidis D. P. (2006).  Dyslipidaemia, hypercoagulability and the metabolic syndrome.. Curr Vasc Pharmacol. 4(3), 175-83.
Mikhailidis, D. P., & Athyros V. G. (2014).  Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.. Nat Rev Cardiol. 11(2), 72-4.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Dyslipidemia as a risk factor for ischemic stroke.. Curr Top Med Chem. 9(14), 1291-7.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.. Open Cardiovasc Med J. 5, 85-9.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Karagiannis, A., Tziomalos K., Anagnostis P., Gossios T. D., Florentin M., Athyros V. G., et al. (2010).  The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.. Curr Vasc Pharmacol. 8(6), 792-803.
Athyros, V. G., Mikhailidis D. P., Didangelos T. P., Giouleme O. I., Liberopoulos E. N., Karagiannis A., et al. (2006).  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.. Curr Med Res Opin. 22(5), 873-83.
Kargiotis, K., Katsiki N., Athyros V. G., Giouleme O., Patsiaoura K., Katsiki E., et al. (2014).  Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.. Curr Vasc Pharmacol. 12(3), 505-11.
Athyros, V. G., Mikhailidis D. P., Liberopoulos E. N., Kakafika A. I., Karagiannis A., Papageorgiou A. A., et al. (2007).  Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.. Nephrol Dial Transplant. 22(1), 118-27.
Anagnostis, P., Papanikolaou D., Ioannidou P. G., Bosdou J. K., Mikhailidis D. P., Hatzimouratidis K., et al. (2021).  The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review.. Andrology. 9(5), 1504-1511.
Athyros, V. G., Katsiki N., Doumas M., Karagiannis A., & Mikhailidis D. P. (2013).  Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review.. Curr Med Res Opin. 29(10), 1263-74.
Katsiki, N., Mikhailidis D. P., Gotzamani-Psarrakou A., Yovos J. G., & Karamitsos D. (2011).  Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus.. Expert Opin Ther Targets. 15(4), 401-20.
Athyros, V. G., Tziomalos K., Kakafika A. I., Koumaras H., Karagiannis A., & Mikhailidis D. P. (2008).  Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.. Am J Cardiol. 101(4), 483-5.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.